Accueil・Liste d'Actions・Royalty Pharma PLC (Class A)

Royalty Pharma PLC (Class A)

Ouvert

SecteurSoins de santé

56.62 -0.82

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

56.57

Max

57.62

Chiffres clés
By Trading Economics
Revenu	-61M 295M
Ventes	8.6M 631M
P/E Moyenne du Secteur	30.09 68.51
BPA	1.3
Rendement du dividende	1.53
Marge bénéficiaire	46.733
Employés	100
EBITDA	112M 563M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+16.14% upside

Dividendes
By Acuity
Rendement du dividende Moyenne du Secteur	1.53% 2.29%
Prochains Résultats	4 nov. 2026
Date du Prochain Dividende	10 sept. 2026
Date du Prochain Détachement de Dividende	14 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	3.2B 33B
Ouverture précédente	57.44
Clôture précédente	56.62

Sentiment de l'Actualité

By Acuity

81%

19%

318 / 340 Classement par Healthcare

Royalty Pharma PLC (Class A) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

6 août 2026, 23:01 UTC

Royalty Pharma PLC shares are higher in after-market trading, moving above Thursday's close, despite remaining below the 20-day moving average.

5 août 2026, 19:31 UTC

News

Royalty Pharma PLC raised its full-year guidance for Portfolio Receipts to $3.4 billion to $3.5 billion, contributing to a higher trading session.

4 août 2026, 19:26 UTC

Royalty Pharma PLC shares are higher today, rebounding after earlier pulling back from a session high. The stock has fluctuated within a routine range.

3 août 2026, 23:46 UTC

Royalty Pharma PLC shares are near unchanged in after-market trading, reflecting minimal movement since Monday's close and remaining below the 20-day moving average.

1 août 2026, 00:03 UTC

Royalty Pharma PLC shares are lower in after-market hours, continuing a decline over the past four sessions. No specific news was identified to explain the move.

31 juil. 2026, 23:01 UTC

Royalty Pharma PLC shares are lower in after-market hours, reflecting broader market trends despite some gains in mega-cap stocks. The stock remains below its 20-day moving average.

30 juil. 2026, 22:01 UTC

Royalty Pharma PLC shares are higher in after-market trading, reflecting strong demand and trading above its 20-day moving average. No specific news was identified.

29 juil. 2026, 19:27 UTC

Royalty Pharma PLC shares are lower today, reflecting a pullback since Tuesday's close amid rising oil prices and inflation concerns.

28 juil. 2026, 23:46 UTC

Royalty Pharma PLC shares are lower in after-market trading, reflecting broader market declines amid concerns over technology sector dynamics.

27 juil. 2026, 16:46 UTC

Royalty Pharma PLC shares are advancing during Monday's session. Broader market gains are supported by a notable decline in oil prices amid easing geopolitical tensions.

24 juil. 2026, 22:21 UTC

In after-market trading, Royalty Pharma PLC is trading higher, nearing the upper end of its one-month range after recovering from an early low.

22 juil. 2026, 19:11 UTC

News

Event

Royalty Pharma acquires a royalty interest in AstraZeneca's cliramitug for up to $425 million, including $125 million upfront payment. Shares are trading roughly flat.

21 juil. 2026, 17:51 UTC

Royalty Pharma PLC shares are higher today, tracking broader market gains, with unusually high trading volume noted. No specific news was identified for the movement.

20 juil. 2026, 19:21 UTC

Royalty Pharma PLC shares are lower as the Pharmaceuticals sector faces downward pressure, with unusually high trading volume noted today.

Comparaison

Variation de prix

Royalty Pharma PLC (Class A) prévision

Objectif de Prix

By TipRanks

16.14% hausse

Prévisions sur 12 Mois

Moyen 66.5 USD 16.14%

Haut 70 USD

Bas 65 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

5 ratings

Achat

Maintien

Vente

Basé sur 5 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

318 / 340Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Royalty Pharma PLC (Class A)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.